Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q2 FY25 results · Jul–Sep 2024
Lincoln Pharmaceuticals reported revenue from operations of ₹161.21 crore (up 3.4% from Q2 FY24) and net profit of ₹26.33 crore (down 4.8% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 161.21 | 155.99 | +3.4% | 147.28 | +9.5% |
| Other income | 9.98 | 8.69 | +14.8% | 10.41 | −4.1% |
| Total income | 171.19 | 164.68 | +4.0% | 157.69 | +8.6% |
| Profit before tax | 34.78 | 36.87 | −5.7% | 29.48 | +18.0% |
| Net profit for the period | 26.33 | 27.65 | −4.8% | 23.67 | +11.2% |
| EPS, basic (₹) | 13.15 | 13.81 | −4.8% | 11.82 | +11.3% |
| Net margin (%) | 16.3 | 17.7 | 16.1 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 161.21 | 155.99 | +3.4% | 147.28 | +9.5% |
| Other income | 9.98 | 8.69 | +14.8% | 10.41 | −4.1% |
| Total income | 171.19 | 164.68 | +4.0% | 157.69 | +8.6% |
| Profit before tax | 34.78 | 36.87 | −5.7% | 29.48 | +18.0% |
| Net profit for the period | 26.33 | 27.65 | −4.8% | 23.67 | +11.2% |
| EPS, basic (₹) | 13.15 | 13.81 | −4.8% | 11.82 | +11.3% |
| Net margin (%) | 16.3 | 17.7 | 16.1 |
Consolidated
- Filed with BSE
- 14 Nov 2024, 14:11 IST
- Board meeting
- 14 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Nov 2024, 14:11 IST
- Board meeting
- 14 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE